Groundbreaking research has revealed that the diabetes and weight-loss drug semaglutide—sold as Ozempic and Wegovy—can significantly reduce the risk of heart attacks and strokes, even for patients who do not lose much weight. The global trial, involving over 17,000 participants across 41 countries, found that semaglutide cut major cardiovascular events by around 14–20%. Researchers discovered that shrinking waist size accounted for about one-third of the benefit, but two-thirds remained unexplained, suggesting the drug directly protects heart health rather than simply improving it through weight loss. Professor John Deanfield of University College London said the results “reframe what we think this medication is doing,” calling it a “disease-modifying therapy for ageing.” Experts describe the findings as “profound,” urging that the drug’s use not be limited to severely obese patients. However, they also cautioned that side effects must be carefully monitored as its use expands. The breakthrough could mark the most significant advance in cardiovascular medicine since statins.